What is the difference between Cartalax and Sigumir?

Both target cartilage and musculoskeletal tissue, but Cartalax is a synthetic single tripeptide (Ala-Glu-Asp), while Sigumir is a natural peptide complex extracted from animal cartilage and bone tissue. Sigumir contains a broader mix of peptides and has more clinical data from the Khavinson program. Cartalax is the simplified, synthetic counterpart.

How does Cartalax relate to type XI collagen?

The AED sequence matches a motif found in the alpha-1 chain of type XI collagen, which is essential for cartilage structure and resilience. The hypothesis is that delivering this sequence exogenously helps reactivate cartilage-maintenance gene programs that decline with age.

Is Cartalax FDA-approved?

No. Cartalax is not FDA-approved and is not used in mainstream Western medicine. Clinical data comes primarily from Russian research institutions associated with the Khavinson bioregulator program. There are no published human RCTs indexed in Western databases.

Cartalax

A synthetic tripeptide bioregulator (Ala-Glu-Asp) from the Khavinson system, studied for cartilage protection, joint health, and musculoskeletal aging.

PreliminaryLimited Data

What is Cartalax?

Cartalax is a synthetic tripeptide consisting of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. Its amino acid sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein important for cartilage integrity. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in cartilage tissue. Its natural-extract counterpart is Sigumir, a complex of peptides derived from animal cartilage and bone tissue.

Why People Talk About It

Cartilage protection and joint health in aging

Preliminary

Osteoarthritis and degenerative joint disease support

Preliminary

Musculoskeletal recovery and bone health

Preliminary

Anti-senescence effects in connective tissue cells

Limited

How It Works

Cartalax is a tiny three-amino-acid peptide proposed to enter cartilage cells and interact with their DNA, reactivating genes involved in maintaining healthy cartilage. As we age, cartilage cells produce less collagen and protective matrix — Cartalax is thought to help reverse that decline by boosting the cell's own repair programs.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesMild injection site irritation (injectable form)Transient mild digestive upset (oral form)

Cautions

• Not FDA-approved
• Clinical data is limited and primarily from Russian research
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

Western clinical trial data is absent. Most evidence comes from the Khavinson research program. Long-term safety of chronic use has not been evaluated in controlled Western studies. The claimed mechanism of direct DNA interaction by a tripeptide remains debated in the broader scientific community.

Published Research

6 studies

Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis

ReviewPMID: 39291443

Peptide Regulation of Chondrogenic Stem Cell Differentiation

PreclinicalPMID: 37109651

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

Mechanism of Action

Cartalax (Ala-Glu-Asp) is proposed to penetrate cell membranes due to its small molecular size (~333 Da) and interact directly with DNA regulatory regions in chondrocytes and fibroblasts. In vitro studies from the Khavinson group report that Cartalax upregulates Ki-67 (proliferation marker), increases SIRT1 and SIRT6 expression (longevity-associated sirtuins), and reduces p53 and caspase-3 activity (pro-apoptotic signals). It inhibits MMP-9 synthesis, an enzyme responsible for extracellular matrix degradation that increases with aging. Cartalax has been reported to increase cartilage area index by 18-38% in chondrocyte cultures from both young and old specimens. The peptide may also modulate Wnt/beta-catenin signaling and stimulate synthesis of type II collagen and aggrecan — both essential for cartilage resilience and elasticity.

Evidence Snapshot

Overall Confidence28%

Human Clinical Evidence

Very limited for Cartalax specifically. A clinical study in the Khavinson program established effectiveness of adjunctive Cartalax treatment in patients with spinal osteochondrosis, osteoarthrosis, and osteoporosis, but this study is not indexed in PubMed. The natural-extract counterpart Sigumir has additional clinical data from Russian studies.

Animal / Preclinical

Moderate within the Khavinson framework. In vitro chondrocyte studies show increased proliferation (18-38% cartilage area index increase), MMP-9 inhibition, SIRT6 upregulation, and reduced senescence markers (p16, p21). The broader Khavinson short-peptide research program demonstrates nuclear penetration and DNA binding by small peptides (PMID: 27909961).

Mechanistic Rationale

Moderate. The AED sequence corresponds to a motif in type XI collagen, providing a structural rationale. The proposed mechanism of cartilage-specific gene reactivation through direct DNA interaction is supported by in vitro data from the originating research group, but has not been independently replicated.

Forms & Administration

Cartalax is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable protocols use subcutaneous administration. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Cartilage protection and joint health in aging

Preliminary30%

Osteoarthritis and degenerative joint disease support

Preliminary30%

Musculoskeletal recovery and bone health

Preliminary30%

Anti-senescence effects in connective tissue cells

Limited15%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in available studiesMild injection site irritation (injectable form)Transient mild digestive upset (oral form)

Cautions

• Not FDA-approved
• Clinical data is limited and primarily from Russian research
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

Published Research

6 studies

Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis

ReviewPMID: 39291443

Peptide Regulation of Chondrogenic Stem Cell Differentiation

PreclinicalPMID: 37109651

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

All references link directly to PubMed. Citations are selected by clinicians for relevance and quality.

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Cortagen

Preliminary

A synthetic peptide bioregulator targeting brain cortex function, studied for cognitive enhancement and neuroprotection in aging.

Pinealon

PreliminaryBeginner

A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.

Vesilute

Preliminary

A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.

Vesugen

Preliminary

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

BPC-157

EmergingBeginner

A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.

Quick Facts

Class: Bioregulator Peptide
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 6PubMed

Also known as

AEDAla-Glu-AspT-31Cartilage Bioregulator

Evidence Score

Overall Confidence28%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.